Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...

H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 ...

Tourmaline Oil Corp. closed 6.2% below its 52-week high of C$70.83, which the company achieved on February 21st.

The market expects Tourmaline Oil Corp. (TRMLF) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known ...

The retail merchandising company is leasing the top floor at Apex at Legacy, owned by Monarch Alternative Capital and ...

Analysts at Wedbush issued their FY2024 EPS estimates for shares of Tourmaline Bio in a research note issued on Thursday, March 6th. Wedbush analyst L. Chico expects that the company will post ...

NEW YORK - Tourmaline Bio, Inc. (NASDAQ: TRML) reported a wider fourth quarter loss on Wednesday, as the clinical-stage biotech company ramped up spending on research and development. Shares fell 2% ...

Read Our Latest Stock Analysis on TRML Tourmaline Bio Trading Down 1.2 % Tourmaline Bio stock opened at $12.79 on Wednesday. Tourmaline Bio has a 1-year low of $11.87 and a 1-year high of $48.31 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Readers hoping to buy Tourmaline Oil Corp. ( TSE:TOU ) for its dividend will need to make their move shortly, as ...